[go: up one dir, main page]

NO2699580T3 - - Google Patents

Info

Publication number
NO2699580T3
NO2699580T3 NO12774761A NO12774761A NO2699580T3 NO 2699580 T3 NO2699580 T3 NO 2699580T3 NO 12774761 A NO12774761 A NO 12774761A NO 12774761 A NO12774761 A NO 12774761A NO 2699580 T3 NO2699580 T3 NO 2699580T3
Authority
NO
Norway
Application number
NO12774761A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2699580(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2699580T3 publication Critical patent/NO2699580T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO12774761A 2014-01-24 2012-04-15 NO2699580T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
NO2699580T3 true NO2699580T3 (fr) 2018-02-24

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12774761A NO2699580T3 (fr) 2014-01-24 2012-04-15

Country Status (39)

Country Link
US (18) US9522894B2 (fr)
EP (4) EP4548972A3 (fr)
JP (7) JP6469711B2 (fr)
KR (1) KR102417684B1 (fr)
CN (2) CN110483492B (fr)
AP (1) AP2016009322A0 (fr)
AR (1) AR099177A1 (fr)
AU (4) AU2015208932C1 (fr)
BR (1) BR112016016224B1 (fr)
CA (1) CA2935625C (fr)
CL (1) CL2016001889A1 (fr)
CR (1) CR20160327A (fr)
CY (2) CY1120049T1 (fr)
DK (3) DK3744714T3 (fr)
DO (1) DOP2016000175A (fr)
EA (1) EA032794B1 (fr)
ES (3) ES2808060T3 (fr)
FI (1) FI3744714T3 (fr)
HK (1) HK1225730B (fr)
HR (3) HRP20180116T1 (fr)
HU (3) HUE070606T2 (fr)
IL (3) IL246614B (fr)
LT (3) LT3744714T (fr)
MX (1) MX368840B (fr)
MY (1) MY194850A (fr)
NO (1) NO2699580T3 (fr)
NZ (2) NZ734768A (fr)
PE (1) PE20161218A1 (fr)
PH (1) PH12016501439B1 (fr)
PL (3) PL3323814T3 (fr)
PT (3) PT3744714T (fr)
RS (3) RS56919B1 (fr)
SG (2) SG10201701056QA (fr)
SI (3) SI3323814T1 (fr)
SM (3) SMT201800058T1 (fr)
TW (1) TWI690517B (fr)
UY (1) UY35963A (fr)
WO (1) WO2015110826A1 (fr)
ZA (2) ZA201605856B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (fr) 2014-01-24 2018-02-24
JP2019522039A (ja) * 2016-07-29 2019-08-08 インスメッド インコーポレイテッド 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
CN112055593B (zh) * 2018-03-01 2024-04-09 阿斯利康(瑞典)有限公司 药物组合物
KR20210032439A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
EP3823627A4 (fr) * 2018-07-17 2022-04-20 Insmed Incorporated Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement d'une néphropathie lupique
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
MX2022004809A (es) * 2019-10-23 2022-05-16 Chong Kun Dang Pharmaceutical Corp Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc).
AU2021314104A1 (en) * 2020-07-20 2023-01-19 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
EP4497473A3 (fr) * 2020-08-26 2025-04-23 Haisco Pharmaceuticals Pte. Ltd. Dérivé de nitrile qui agit en tant qu'inhibiteur de la dipeptidyl peptidase 1 et son utilisation
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
EP4257588A4 (fr) * 2020-12-04 2024-10-16 Reistone Biopharma Company Limited Inhibiteur à petites molécules de la cathepsine c et son utilisation médicinale
WO2022140516A1 (fr) * 2020-12-22 2022-06-30 Insmed Incorporated Certains ((25)-iv-[(ls')~ i-c yan0-2-phényléthyl·]-1,4-oxazépane-2-carboxamides pour le traitement de la maladie de behçet
JP7693817B2 (ja) * 2021-02-05 2025-06-17 エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド １，４－オキサゼパンを含む縮合環誘導体
EP4329767A4 (fr) * 2021-04-29 2025-03-12 Insmed Incorporated <smallcaps/>? ? ?n? ? ? ? ?certains-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement de la fibrose kystique
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
US20250049813A1 (en) * 2021-10-29 2025-02-13 Insmed Incorporated Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
US20250101011A1 (en) * 2022-01-11 2025-03-27 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd Peptidyl nitrile compound and use thereof
IL314769A (en) * 2022-02-16 2024-10-01 Insmed Inc Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
JP2025505824A (ja) 2022-02-22 2025-02-28 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ１阻害剤結晶多形体及びその製造方法と用途
CN118742547A (zh) 2022-02-22 2024-10-01 西藏海思科制药有限公司 一种含氮杂环化合物的制备方法
CN118660873A (zh) * 2022-02-22 2024-09-17 西藏海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
EP4538271A4 (fr) 2022-06-07 2025-10-08 Reistone Biopharma Company Ltd Polymorphe de composé benzo[c]chromane, son procédé de préparation et son utilisation
AU2023285191A1 (en) 2022-06-07 2024-12-12 Reistone Biopharma Company Limited Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
KR20250022023A (ko) 2022-06-13 2025-02-14 알리벡시스 가부시키가이샤 아자사이클로알킬카보닐 환상 아민 화합물
EP4551554A1 (fr) 2022-07-06 2025-05-14 Chiesi Farmaceutici S.p.A. Dérivés d'azétidine et leur utilisation comme inhibiteurs de la dipeptidyl peptidase 1
WO2024081889A1 (fr) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Dérivés de 4h-pyrido[1,2-a]pyrimidin-4-one pour le traitement du cancer
WO2024088307A1 (fr) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 Nouveau composé peptidylnitrile et son utilisation
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
AU2024206233A1 (en) 2023-01-06 2025-08-21 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2024173556A2 (fr) * 2023-02-15 2024-08-22 Insmed Incorporated Utilisations de certains 1,4-oxazépane-2-carboxamides en tant qu'inhibiteurs de dpp1
AU2024241242A1 (en) 2023-03-23 2025-11-06 Haisco Pharmaceuticals Pte. Ltd. Pharmaceutical composition containing dipeptidyl peptidase small molecule inhibitor
WO2025059526A1 (fr) * 2023-09-15 2025-03-20 Insmed Incorporated Inhibiteurs de la dipeptidyl peptidase 1 et leurs utilisations
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (fr) * 2024-04-12 2025-10-16 Insmed Incorporated Inhibiteurs de la dipeptidyl peptidase 1 et leurs utilisations

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2002020804A1 (fr) 2000-09-08 2002-03-14 Prozymex A/S Structure de cristal peptidase dipeptidyl i et son utilisation
AU9419701A (en) * 2000-10-06 2002-04-22 Tanabe Seiyaku Co Aliphatic nitrogenous five-membered ring compounds
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
EP1453801B1 (fr) 2001-12-04 2007-03-21 F. Hoffmann-La Roche Ag 2-amino-cycloalkanecarboxamides substitues et leur utilisation en tant qu'inhibiteurs de la cysteine protease
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (fr) 2003-02-28 2004-09-10 Aic Inhibiteurs de dipeptidyl peptidases
EP1608369B1 (fr) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Utilisation de composés organiques pour l'immunopotentialisation
ES2308181T3 (es) 2003-05-30 2008-12-01 Prozymex A/S Inhibidores de proteasa.
WO2004110988A1 (fr) 2003-06-18 2004-12-23 Prozymex A/S Inhibiteurs de la protease
NZ549990A (en) 2004-04-07 2009-08-28 Rinat Neuroscience Copr Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2005106012A2 (fr) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
CN101513391B (zh) 2004-06-29 2013-03-13 奈科明丹麦股份有限公司 水不溶性药快速释放药物组合物的制造方法及通过本方法得到的药物组合物
AU2005274852B2 (en) 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
BRPI0607809A2 (pt) 2005-02-18 2009-06-13 Abraxis Bioscience Inc uso de uma composição compreendendo nanopartìculas, composição e kit
WO2007005668A2 (fr) 2005-06-30 2007-01-11 Amgen Inc. Inhibiteurs de bis-aryl kinase et methode associee
US20080221094A1 (en) 2007-03-07 2008-09-11 Harald Bluhm Metalloprotease inhibitors containing a squaramide moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
MX2010003263A (es) 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
KR20100098683A (ko) * 2007-12-12 2010-09-08 아스트라제네카 아베 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
RU2586212C2 (ru) 2008-12-08 2016-06-10 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
CN102438595B (zh) 2009-04-01 2016-04-27 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
EP2427445A1 (fr) * 2009-05-07 2012-03-14 AstraZeneca AB Composés 1-cyanoéthylhétérocyclylcarboxamide substitués 750
WO2010142985A1 (fr) * 2009-06-10 2010-12-16 Astrazeneca Ab Composés 761 n-[1-cyano-2-(phényle)éthyle]pipéridine-2-ylcarboxamide substitués
CN106943403A (zh) 2010-04-07 2017-07-14 弗特克斯药品有限公司 药物组合物和其给药方法
WO2011154677A1 (fr) * 2010-06-09 2011-12-15 Astrazeneca Ab Composés n-[1-cyano-2-(phényl)éthyl] 1-aminocycloalk-1-ylcarboxamide substitués - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
EP2672821B9 (fr) 2011-02-11 2016-11-23 GlaxoSmithKline Intellectual Property Development Limited Inhibiteurs de la cathepsine c
WO2012119941A1 (fr) 2011-03-04 2012-09-13 Prozymex A/S Composés de peptidylnitrile à titre d'inhibiteurs de peptidases
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EP2817310B1 (fr) 2012-02-21 2018-03-21 Merck Patent GmbH 2-amino-[1,2,4]triazolo[1,5-a]pyrazines substituées en 8ème position en tant qu'inhibiteurs de la tyrosine kinase syk et en tant qu'inhibiteurs de la sérine kinase gcn2
MX355055B (es) 2012-04-17 2018-04-03 Astellas Pharma Inc Compuesto heterociclico aromatico biciclico nitrogenado.
WO2014091443A1 (fr) 2012-12-13 2014-06-19 Glaxo Group Limited Inhibiteurs de la cathepsine c pour traiter la mucoviscidose, la bronchectasie sans fibrose kystique, et la vascularite associée aux anca
EP2775304A1 (fr) 2013-03-07 2014-09-10 Universitätsspital Basel Procédés de détection de troubles inflammatoires
US8877775B2 (en) 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
WO2014140078A1 (fr) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Inhibiteurs de cathepsine c de type (cyano-méthyl)-amides d'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique substitué
WO2014140081A1 (fr) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Inhibiteurs 1-acide carboxylique (benzyl-cyano-methyl)-amides bicycliques substitués de la cathépsine c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015027039A1 (fr) 2013-08-22 2015-02-26 Emory University Dispositifs et procédés relatifs à une inflammation des voies aériennes
CA2923484C (fr) 2013-09-09 2022-09-06 Prozymex A/S Composes de peptidyl-nitrile en tant qu'inhibiteurs de dipeptidyl-peptidase i
WO2015032942A1 (fr) 2013-09-09 2015-03-12 Prozymex A/S 3,3'-(biphényl-4,4'-diyl)bis-2-aminopropanenitriles substitués en n en tant qu'inhibiteurs dppi
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (fr) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
RU2020107732A (ru) 2014-04-10 2020-03-30 Новартис Аг Схема дозирования модулятора s1p с немедленным высвобождением
AU2015258947B2 (en) 2014-05-15 2020-04-09 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2015180687A1 (fr) 2014-05-30 2015-12-03 The University Of Hong Kong Procédés et compositions permettant d'utiliser l'élastase neutrophile et la protéinase 3 en tant que biomarqueurs de diagnostic
EP3174879B1 (fr) 2014-08-01 2018-07-18 Boehringer Ingelheim International GmbH Oxétanes substitués et leur utilisation en tant qu'inhibiteurs de la cathépsine c
AP2017009733A0 (en) 2014-09-12 2017-02-28 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
CA2965566A1 (fr) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Amides de morpholine et de 1,4-oxazepane utilises en tant qu'agonistes du sous-type 4 du recepteur de la somatostatine (sstr4)
JP6783426B2 (ja) 2015-03-05 2020-11-11 ニュープロザイム・セラピューティクス・アンパルトセルスカブＮｅｕｐｒｏｚｙｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡｐＳ ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物
JP2019522039A (ja) 2016-07-29 2019-08-08 インスメッド インコーポレイテッド 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
AU2019217870A1 (en) 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
CN112055593B (zh) 2018-03-01 2024-04-09 阿斯利康(瑞典)有限公司 药物组合物
EP3823627A4 (fr) 2018-07-17 2022-04-20 Insmed Incorporated Certains (2s)-n-[(1s)-1-cyano-2-phényléthyl]-1,4-oxazépane-2-carboxamides pour le traitement d'une néphropathie lupique
KR20210032439A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN114206312A (zh) 2019-04-17 2022-03-18 阿佐拉治疗股份有限公司 用于治疗炎性皮肤病的局部组合物和方法
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
WO2022140516A1 (fr) 2020-12-22 2022-06-30 Insmed Incorporated Certains ((25)-iv-[(ls')~ i-c yan0-2-phényléthyl·]-1,4-oxazépane-2-carboxamides pour le traitement de la maladie de behçet
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (fr) 2021-04-29 2022-11-03 Insmed Incorporated Certains n-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement du cancer
EP4329767A4 (fr) 2021-04-29 2025-03-12 Insmed Incorporated <smallcaps/>? ? ?n? ? ? ? ?certains-(1-cyano-2-phényléthyl)-1,4-oxazépane-2-carboxamides pour le traitement de la fibrose kystique
US20250049813A1 (en) 2021-10-29 2025-02-13 Insmed Incorporated Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
IL314769A (en) 2022-02-16 2024-10-01 Insmed Inc Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Also Published As

Publication number Publication date
CN105980367B (zh) 2019-08-23
US11667615B2 (en) 2023-06-06
MY194850A (en) 2022-12-19
US20200017455A1 (en) 2020-01-16
AU2015208932B8 (en) 2017-03-09
US20230025351A1 (en) 2023-01-26
EP4548972A2 (fr) 2025-05-07
SI3323814T1 (sl) 2020-10-30
JP2025157389A (ja) 2025-10-15
US20230033573A1 (en) 2023-02-02
JP7336563B2 (ja) 2023-08-31
JP2025072423A (ja) 2025-05-09
DK3097086T3 (en) 2018-02-05
MX368840B (es) 2019-10-18
CN110483492A (zh) 2019-11-22
US20210238152A1 (en) 2021-08-05
BR112016016224B1 (pt) 2023-02-23
BR112016016224A2 (fr) 2017-08-08
NZ734768A (en) 2022-09-30
KR102417684B1 (ko) 2022-07-05
US20230116721A1 (en) 2023-04-13
IL265611A (en) 2019-05-30
EP3744714B1 (fr) 2025-01-15
JP2021046423A (ja) 2021-03-25
SMT201800058T1 (it) 2018-03-08
PL3323814T3 (pl) 2020-10-19
PL3097086T3 (pl) 2018-04-30
RS66709B1 (sr) 2025-05-30
JP7714823B2 (ja) 2025-07-29
RS60639B1 (sr) 2020-09-30
US20230278969A1 (en) 2023-09-07
PH12016501439A1 (en) 2017-02-06
US20150210655A1 (en) 2015-07-30
US20240336582A1 (en) 2024-10-10
SG11201606052TA (en) 2016-08-30
US20170057938A1 (en) 2017-03-02
HRP20180116T1 (hr) 2018-03-23
US20230062646A1 (en) 2023-03-02
AU2015208932B2 (en) 2017-02-16
SMT202000433T1 (it) 2020-09-10
JP2023156479A (ja) 2023-10-24
CA2935625C (fr) 2022-10-18
TW201612167A (en) 2016-04-01
US20240132455A1 (en) 2024-04-25
EP3323814B1 (fr) 2020-05-13
US20180251436A1 (en) 2018-09-06
ES3018635T3 (es) 2025-05-16
US20230085620A1 (en) 2023-03-23
ES2658516T3 (es) 2018-03-12
HRP20201147T1 (hr) 2020-12-11
US11673871B2 (en) 2023-06-13
DK3323814T3 (da) 2020-08-03
US20230115170A1 (en) 2023-04-13
AU2018202956B2 (en) 2019-05-09
SG10201701056QA (en) 2017-03-30
DOP2016000175A (es) 2016-08-15
CR20160327A (es) 2016-10-20
US10669245B2 (en) 2020-06-02
EA032794B1 (ru) 2019-07-31
US10287258B2 (en) 2019-05-14
US11655221B2 (en) 2023-05-23
TWI690517B (zh) 2020-04-11
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
EP3097086B1 (fr) 2017-12-13
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
AU2015208932C1 (en) 2017-05-25
AR099177A1 (es) 2016-07-06
CL2016001889A1 (es) 2016-12-09
HRP20250302T1 (hr) 2025-04-25
US11655224B2 (en) 2023-05-23
US11673872B2 (en) 2023-06-13
NZ722063A (en) 2017-09-29
EA201691375A1 (ru) 2017-01-30
CY1120049T1 (el) 2018-12-12
MX2016009349A (es) 2016-10-13
PT3744714T (pt) 2025-04-07
CA2935625A1 (fr) 2015-07-30
JP2019070029A (ja) 2019-05-09
CN105980367A (zh) 2016-09-28
PL3744714T3 (pl) 2025-09-08
JP7628587B2 (ja) 2025-02-10
US11814359B2 (en) 2023-11-14
AU2018202956A1 (en) 2018-05-17
JP7157791B2 (ja) 2022-10-20
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (fr) 2020-12-02
PE20161218A1 (es) 2016-11-27
LT3744714T (lt) 2025-04-10
JP2022096662A (ja) 2022-06-29
JP2017503832A (ja) 2017-02-02
AU2019202675A1 (en) 2019-05-16
EP3097086A1 (fr) 2016-11-30
JP6804570B2 (ja) 2020-12-23
US20200247765A1 (en) 2020-08-06
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
AP2016009322A0 (en) 2016-07-31
HUE052421T2 (hu) 2021-04-28
WO2015110826A1 (fr) 2015-07-30
SI3097086T1 (en) 2018-04-30
PH12016501439B1 (en) 2017-02-06
ZA201605856B (en) 2020-02-26
LT3097086T (lt) 2018-02-26
SI3744714T1 (sl) 2025-05-30
US11680049B2 (en) 2023-06-20
US11117874B2 (en) 2021-09-14
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
IL252836A0 (en) 2017-08-31
HK1255870A1 (en) 2019-08-30
US20230250071A1 (en) 2023-08-10
EP3323814A1 (fr) 2018-05-23
US9815805B2 (en) 2017-11-14
CY1123391T1 (el) 2021-12-31
KR20160111470A (ko) 2016-09-26
HK1225730B (en) 2017-09-15
SMT202500137T1 (it) 2025-05-12
JP6469711B2 (ja) 2019-02-13
ZA201800431B (en) 2019-09-25
US20230028726A1 (en) 2023-01-26
US11655223B2 (en) 2023-05-23
US20230069044A1 (en) 2023-03-02
US11655222B2 (en) 2023-05-23
AU2015208932A1 (en) 2016-07-28
EP4548972A3 (fr) 2025-06-25
AU2015208932A8 (en) 2017-03-09
PT3323814T (pt) 2020-08-05
AU2019202675B2 (en) 2020-05-28
LT3323814T (lt) 2020-10-26
DK3744714T3 (da) 2025-04-07
US9522894B2 (en) 2016-12-20
HUE070606T2 (hu) 2025-06-28
AU2017200338B2 (en) 2018-03-01
US12054465B2 (en) 2024-08-06
CN110483492B (zh) 2023-07-21

Similar Documents

Publication Publication Date Title
BR112014021090A2 (fr)
BR112014017614A2 (fr)
BR112014017625A2 (fr)
BR112014017659A2 (fr)
BR112014017592A2 (fr)
BR112014017607A2 (fr)
BR112014017646A2 (fr)
BR112014017638A2 (fr)
AR092201A1 (fr)
BR112014020246A2 (fr)
BR112014017755A2 (fr)
BR112014017609A2 (fr)
BR112014019371A2 (fr)
BR112014017644A2 (fr)
BR112014018739A2 (fr)
BR112014017618A2 (fr)
BR112014017647A2 (fr)
BR112014017623A2 (fr)
BR112014017652A2 (fr)
BR112014017627A2 (fr)
BR112014018617A2 (fr)
BR112014017641A2 (fr)
BR112014017622A2 (fr)
BR112014019870A2 (fr)
BR112014019729A2 (fr)